Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat

Journal of Bone and Mineral Metabolism

Volumn 26, Issue 4, 2008, Pages 406-408

  Bauss, Frieder ^a   Pfister, Thomas ^b   Papapoulos, Socrates ^c  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Jaw; ONJ; Osteonecrosis

Indexed keywords

IBANDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BONE LEVEL; DRUG UPTAKE; DRY WEIGHT; FEMUR; GAS CHROMATOGRAPHY; LUMBAR VERTEBRA; MALE; MANDIBLE; MASS SPECTROMETRY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; DIPHOSPHONATES; FEMUR; JAW; MALE; RATS; RATS, WISTAR; SPINE;

EID: 46749130481     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-007-0837-x     Document Type: Article

References (9)

1. Migliorati CA, Siegel MA, Etting LS (2006) Bisphosphonateassociated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7:508-514. Erratum in: (2007) Lancet Oncol 7:533
2. Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761. Erratum in: (2006) Ann Intern Med 145:235
3. Ruggiero SL, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V (2006) Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7-14
4. Somerman MJ, McCauley LK (2006) Bisphosphonates: sacrificing the jaw to save the skeleton? BoneKEy-Osteovision 3:12-18
5. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643-2658
6. Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 41:318-320
7. Endele R, Loew H, Bauss F (2005) Analytical methods for the quantification of ibandronate in body fluids and bone. J Pharm Biomed Anal 39:246-256
8. Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H (1991) BM 21.0955 a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011
9. Lin JH, Duggan DE, Chen I-W, Ellsworth RL (1991) Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 19:926-932